论文部分内容阅读
目的观察尼莫地平对原发性开角型青光眼的治疗效果。方法原发性开角型青光眼患者22例(36眼),分为两组,两组患者的眼压均控制在18mmHg以下,其中一组予口服尼莫地平,治疗前后分别检测视力、眼压和视野(用视网膜平均光敏感度代表),采用t检验和掊2检验比较两组之间的差异。结果治疗6、12个月时,尼莫地平组的视网膜平均光敏感度分别为(16.48±3.05)dB和(16.05±2.47)dB,对照组分别为(12.36±2.64)dB和(10.49±2.58)dB,两组比较有显著性差异(t=4.43,6.54,P﹤0.01)。治疗12个月时,尼莫地平组有2眼出现视野进行性损害,对照组有7眼出现视野进行性损害,两组比较有显著性差异(X2=5.40,P﹤0.05)。治疗前后各时间段两组的眼压和视力无显著性差异。应用尼莫地平的患者未出现明显的药物不良反应。结论尼莫地平可能有利于保护或改善青光眼患者的视野。
Objective To observe the therapeutic effect of nimodipine on primary open-angle glaucoma. Methods Twenty-two patients (36 eyes) with primary open-angle glaucoma were divided into two groups. The intraocular pressure was controlled below 18mmHg in both groups. One group was given nimodipine before and after the treatment. The visual acuity and intraocular pressure And field of view (represented by the average photosensitivity of the retina), t-test and 掊 2 test were used to compare the differences between the two groups. Results At 6 and 12 months of treatment, the average photosensitivity of the retina in the nimodipine group was (16.48 ± 3.05) dB and (16.05 ± 2.47) dB, respectively, and (12.36 ± 2.64) dB and (10.49 ± 2.58) dB, there was significant difference between the two groups (t = 4.43,6.54, P <0.01). At 12 months of treatment, 2 eyes of the nimodipine group had progressive visual field damage, and 7 eyes of the control group had progressive visual field injury (X2 = 5.40, P <0.05). There was no significant difference in intraocular pressure and visual acuity between the two groups before and after treatment. Nimodipine patients did not appear obvious adverse drug reactions. Conclusion Nimodipine may be beneficial in protecting or improving glaucoma patients’ vision.